Grant of Options

Stem Cell Sciences plc
05 July 2007


For Immediate Release                                               05 July 2007

                             Stem Cell Sciences plc

                                Grant of Options

Stem Cell Sciences plc, the global biotechnology company focused on the
commercialisation of stem cells and stem cell technologies in research and
cell-based therapies, announces that on 19th June 2007 the following Directors
of the Company were granted options over Ordinary Shares in the Company as
follows:

-   DAVID A DODD, NON-EXECUTIVE CHAIRMAN, has been granted options to acquire
250,000 new Ordinary Shares in the Company at a price of 42 pence per share;

-   JEREMY P SCUDAMORE, NON-EXECUTIVE DIRECTOR, has been granted options to
acquire 50,000 new Ordinary Shares in the Company at a price of 42 pence per
share;

-   LES H WEBB, NON-EXECUTIVE DIRECTOR has been granted options to acquire
50,000 new Ordinary Shares in the Company at a price of 42 pence per share.
Subsequent to the grant of these options, Les Webb will hold a total of 112,400
options over ordinary shares.

- HARRY KARELIS, NON-EXECUTIVE DIRECTOR has been granted options to acquire
50,000 new Ordinary Shares in the Company at a price of 42 pence per share.
Subsequent to the grant of these options, Harry Karelis will hold a total of
100,000 options over ordinary shares.

The options vest over a four year period and the strike price is based upon the
average price of the three previous days trading to the grant date of 19th June
2007.

                                    - Ends -

For further information, please contact:

Stem Cell Sciences plc (United Kingdom)
Sue Furber, Director of Finance and Company Secretary           [phone]

Notes to Editors
Stem Cell Sciences plc (SCS, AIM: STEM, ASX: STC) is a global biotechnology
company providing the biological infrastructure of cells and cell culture media
to the burgeoning stem cell research market.

Stem Cell Sciences' core objective is to develop safe and effective cell-based
therapies for currently incurable diseases. SCS retains all rights to its
technology for therapeutic use and is targeting cell-based therapies for
neurodegenerative disease and injury.

Revenues from Stem Cell Sciences' research business are delivered via an
integrated network of business teams and regional offices in Edinburgh and
Cambridge (UK), Kobe (Japan), Melbourne (Australia) and San Francisco (USA).
This global reach provides the Company with the direct access to markets through
experienced personnel and local business networks needed to drive SCS business
growth in each region.

The key challenge for the successful application of stem cells in both research
and clinical applications is the reproducible supply of pure, fully
characterized stem cells and stem cell-derived specialised cells such as nerves
and muscle. This represents a significant technological challenge that will
require access to multiple technologies and a globally integrated stem cell
initiative.

To access cutting edge technologies on a rapid and on-going basis, Stem Cell
Sciences has built an exceptional network of highly interactive collaborations
with academic centres of excellence in the stem cell field. These collaborations
have been the source of our founding technologies and continue to provide an
expanding pipeline of products and intellectual property that are central to the
Company's strategy and success.

To facilitate research and technology transfer with its major collaborating
academic institutions, Stem Cell Sciences' business and scientific teams are
usually co-located on site or adjacent to the centre of excellence in
independent company facilities. The Company's key collaborating institutes
include the Wellcome Trust Centre for Stem Cell Research (University of
Cambridge), the Institute of Stem Cell Research (University of Edinburgh), RIKEN
Centre for Developmental Biology (Kobe) and the Australian Stem Cell Centre
(Melbourne).

Academic and commercial use of stem cells in basic research and drug discovery
provides the Company with immediate and growing revenue streams and offsets the
cost of technology development for full scale cell production of SCS cell-based
therapeutics.

For further information on the company please visit:www.stemcellsciences.com



                      This information is provided by RNS
            The company news service from the London Stock Exchange